News

An ongoing experiment at the International Space Station may help identify triggers for multiple sclerosis (MS) and Parkinson’s disease by studying how nerve cells and immune cells interact when exposed to microgravity. Using patient-derived cells, researchers will study the way nerve cells grow, survive, and change their gene…

Valeritas Holdings‘ proprietary h-Patch device can be used to administer cannabidiol by an under-the-skin (subcutaneous) infusion, prolonging the time the medication remains in circulation in the body and maximizing its therapeutic effects, a preclinical study has found. Cannabidiol (CBD) is a cannabis-derived, purified liquid formulation that has…

Vaccines are not a risk factor for multiple sclerosis (MS), a large data analysis spanning more than 12,250 MS patients in Germany shows. Fewer vaccinations were given to people who — five years later — would be diagnosed with MS, compared to those who would be diagnosed with…

The Multiple Sclerosis (MS) and Parkinson's Tissue Bank at Imperial College London, the largest brain and tissue bank in Europe, will receive £1.5 million (about $1.82 million) from the U.K. MS Society. This fund will support the development of a digital brain bank powered by a virtual reality platform, which will provide new tools for researchers around the world with the ultimate goal of stopping multiple sclerosis (MS) and other neurological diseases. These new technologies will be used to create high-definition pictures of brain tissue donated by people with MS after their death. “When the tissue bank first opened in 1998 there were practically no treatments for those affected. Things are very different now and it’s a privilege to work with an organization like the MS Society, which does everything it can to ensure the work of the scientific community reflects the needs of people living with MS," Richard Nicholas, PhD, scientific director of the tissue bank, said in a press release. “This investment will ensure all researchers have access to high quality brain and spinal cord tissue from people with MS, and marks an important development in the U.K. research landscape. We’re excited to see where it takes us,” Nicholas added. The new-era tissue bank will grant researchers access to tissue images that can be studied extensively and indefinitely, and also will offer the opportunity to explore the brain’s structures in a 3-D interactive section. Together with Parkinson's UK, these two leading neurological charities will contribute a total of £3 million (about $3.6 million) over a period of five years. "The MS Society Tissue Bank has been vital in improving our understanding of MS and finding treatments for some people with the condition. But our top priority now is finding treatments to slow or stop MS for everyone,” said Sorrel Bickley, PhD, head of biomedical research at MS Society. This new virtual database gives researchers the opportunity to develop innovative projects in which they can combine virtual tissue data with genetic analysis in an easy and more efficient way, and help define how genetic landscape can affect MS and Parkinson’s progression. “We can see a future where nobody needs to worry about MS getting worse, but for that to happen we urgently need to find treatments that repair myelin — the protective layer that surrounds our nerves, which is damaged in MS, and protect the nerves from damage. This funding will allow researchers to operate as effectively as possible, and ultimately help us stop MS faster,” Bickley said.

The development of new medicines to treat myelin-related neurological diseases, such as multiple sclerosis (MS), has been given a boost by a €2.9 million (about $3.2 million) research grant awarded to the Belgian biotech company Rewind Therapeutics by…

Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New Jersey designed specifically to support children with multiple sclerosis (MS). The support program seeks to promote children’s access to cutting-edge therapies and clinical trials, and to educate…

Fewer and less severe gastrointestinal (GI) side effects were evident in relapsing-remitting multiple sclerosis (RRMS) patients taking the investigational oral treatment Vumerity (diroximel fumarate) twice a day compared to those using Tecfidera (dimethyl fumarate), topline data from the EVOLVE-MS-2 trial show. Vumerity is a fumarate compound being developed…

No excessive relapse risk appears to exist for people with multiple sclerosis who undergo surgery that requires anesthesia, researchers report, challenging long-held assumptions associated with MS and surgery. Their single-site study, “Multiple sclerosis relapse risk in the postoperative period: Effects of…

A new diagnostic method for multiple sclerosis (MS) that uses 3D analysis of a patient’s brain may be able to tell physicians which lesions there are more likely to heal with time and which are not, and as such could be a game-changer in treating the disease, according to the…

Routine screening through magnetic resonance imaging (MRI) of people with multiple sclerosis (MS) can predict long-term disease progression — leading to more certainty and informing better treatment choices, a 15-year study reported. The study, titled “Early imaging predictors of long-term…

Janssen has announced positive, top-line results from its Phase 3 OPTIMUM study, testing the effectiveness and safety of ponesimod tablets, compared to Sanofi‘s Aubagio (teriflunomide), in adults with relapsing forms of multiple sclerosis (MS). The study met its primary goal — a reduction in the…

Early and continuous treatment with Gilenya (fingolimod) in young  people — those ages 30 years or younger — with relapsing-remitting multiple sclerosis (RRMS) decreases the risk of disability progression, and lowers annual relapse rates and brain lesions, new analysis from the FREEDOMS and FREEDOMS II trials show. The…

The National Institutes of Health (NIH) awarded a $1.83 million grant to a Kessler Foundation researcher leading a clinical trial to test if a month-long cognitive training program can improve learning and memory in adults with multiple sclerosis (MS). Nancy Chiaravalloti, PhD, director of the Centers…

The nerve cell circuit, stretching from the skin to the spinal cord, that is likely responsible for the persistent itching sensation  that can afflict people with multiple sclerosis (MS) and other conditions was identified in a study.

Celgene and the Multiple Sclerosis Association of America (MSAA) are working together to bring the “MS MindShift: A New View of MS” campaign, which is raising awareness about the importance of brain health in multiple sclerosis (MS), to the 37th Annual QuickChek New Jersey Festival of Ballooning in Readington,…

A first healthy volunteer has enrolled in a randomized, double-blind Phase 1 study to compare the gastrointestinal (GI) tolerability and safety of oral Tecfidera to Bafiertam, an oral bioequivalent in treating relapsing forms of multiple sclerosis (MS), Banner Life Sciences…

Scientists identified and “fingerprinted” a group of T-helper cells that are unusually numerous in the blood and central nervous system of people with relapsing-remitting multiple sclerosis (RRMS), and may be the reason behind the neuroinflammation seen in these patients. This T-cell population carries specific markers involved in the transmission…

People whose advanced progressive multiple sclerosis (MS) limits their mobility can strengthen their lower limbs and improve life quality by engaging in regular standing exercises in their homes, a U.K. study into physiotherapy programs for this patient group reports. The study, “Assessment…

The percentage of Taiwanese who develop multiple sclerosis (MS) after an episode of clinically isolated syndrome (CIS) is lower than that reported for other ethnicities, and those who do progress are likely to have a milder disease course, a study found, supporting how factors like geography and genetics…

An antiviral medication called amantadine and ondansetron, which treats chronic nausea, both work to reduce fatigue in people with multiple sclerosis (MS), but amantadine may be more effective, a single-site trial in Iran reports. The study, “Comparison of the effects of amantadine and ondansetron in treatment…

Gilenya (fingolimod) has been approved in China as a disease-modifying therapy to treat adults and children, ages 10 and older, with relapsing forms of multiple sclerosis (MS). Gilenya, marketed by Novartis, is an oral disease-modifying treatment for relapsing MS. It acts by binding and modulating receptors…

Projection neurons, a specific type of nerve cell, are prone to damage in the brain of people with multiple sclerosis (MS), and could be at the root of brain atrophy (shrinkage) and the cognitive changes seen in patients. Looking at individual cells in the brain, scientists found…

Gut microbes prime immune cells called microglia to protect the brain and nervous system from neurological damage due to viral infections, according to new research in mice. The findings suggest that maintaining a healthy and diverse microbiota — the population of bacteria, fungi, and viruses within the body, especially the…

Obesity may increase the risk for the development and progression of multiple sclerosis (MS) in children and teens, and it may prevent first-line MS therapies from working. Those findings were reported in the study “Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease…

Convelo Therapeutics has announced a collaboration with Genentech, a member of the Roche Group, to work toward the development of new remyelination therapies for multiple sclerosis (MS) and other myelin disorders. “We are excited to be working with Genentech to…

The cerebrospinal fluid (CSF) of people with progressive multiple sclerosis (MS) contains elevated levels of specific fatty molecules that disrupt the energy “powerhouses” of nerve cells, and appear to underlie the neurodegeneration seen on brain scans of these patients, a study reveals. The research, which compared the CSF…

Treating people with relapsing forms of multiple sclerosis (MS) with opicinumab and Avonex (interferon beta-1a) for 72 weeks did not lead to a dose-dependent reduction in disability,  results of a Phase 2 trial show. However, an ongoing study is evaluating opicinumab in a subgroup with better clinical responses.

A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request…

A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…

A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical company that is developing an ISP-like compound — NVG-291 — for the treatment of nerve injury and MS. The study,…